ADMA Biologics (ADMA)
US Market

ADMA Biologics (ADMA) Income Statement


ADMA Biologics Income Statement

Last quarter (Q1 2024), ADMA Biologics's total revenue was $81.88M, an increase of 43.86% from the same quarter last year. In Q1, ADMA Biologics's net income was $17.81M. See ADMA Biologics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 283.18M$ 258.21M$ 154.08M$ 80.94M$ 42.22M$ 29.35M
Cost of Revenue
$ 171.64M$ 169.27M$ 118.81M$ -79.77M$ 61.29M$ 39.50M
Gross Profit
$ 111.54M$ 88.94M$ 35.27M$ 1.17M$ -19.07M$ -10.16M
Operating Expense
$ 67.27M$ 67.31M$ 74.63M$ -59.55M$ 45.84M$ 31.27M
Operating Income
$ 44.25M$ 21.63M$ -39.37M$ -58.37M$ -64.91M$ -41.42M
Net Non Operating Interest Income Expense
$ -20.85M$ -23.41M$ -19.23M$ -13.02M$ -11.70M$ -8.19M
Other Income Expense
$ 26.47M$ 26.46M$ 126.12M$ 251.57K$ 863.27K$ 1.34M
Pretax Income
$ -3.00M$ -28.21M$ -65.90M$ -71.65M$ -75.75M$ -48.28M
Tax Provision
$ -163.00K$ -763.00K$ -1.77M$ -231.47K--
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -3.60M$ -28.24M$ -65.90M$ -71.65M$ -75.75M$ -48.28M
Basic EPS
$ -0.02$ -0.13$ -0.33$ -0.51$ -0.88$ -0.89
Diluted EPS
$ -0.02$ -0.13$ -0.33$ -0.51$ -0.88$ -0.89
Basic Average Shares
$ 902.86M$ 223.98M$ 197.87M$ 139.58M$ 86.15M$ 54.35M
Diluted Average Shares
$ 910.40M$ 223.98M$ 197.87M$ 139.58M$ 86.15M$ 54.35M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 238.91M$ 236.58M$ -193.44M$ -139.32M$ 107.13M$ 70.77M
Net Income From Continuing And Discontinued Operation
$ -3.64M$ -28.24M$ -65.90M$ -71.65M$ -75.75M$ -48.28M
Normalized Income
$ -286.94K$ -25.14M--$ -76.74M$ -49.84M
Interest Expense
----$ 11.99M$ 8.99M
$ 6.26M$ -21.24M$ -60.50M$ -69.75M$ -63.76M$ -39.29M
$ 16.89M$ -10.46M$ -51.13M$ -62.50M$ -59.82M$ -36.03M
Currency in USD

ADMA Biologics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis